One phase 2 clinical trial highlighted the potential of CDK4 inhibitor ribociclib in combination with the MEK inhibitor binimetinib as a treatment approach in melanoma, particularly in cases with specific genetic alterations involving CDK4. The gene discussed is CDK4; the disease is melanoma.